Stay updated on Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.

Latest updates to the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page
- Check3 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2 on the page.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision: v3.4.3 has been added and Revision: v3.4.2 has been removed.SummaryDifference0.0%

- Check61 days agoChange DetectedAdministrative revision updates were applied: Revision v3.4.2 was added and Revision v3.4.1 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedAdded Revision: v3.4.1 and removed the government-funding notice and the earlier Revision: v3.4.0 entry.SummaryDifference0.1%

- Check76 days agoChange DetectedA site-wide notice about a lapse in government funding has been added, informing users that information on the site may not be up to date and that the NIH Clinical Center is open, with links for further details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.